StoneX Group’s MAIA Biotechnology MAIA Stock Holding History

StoneX Group’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,249	Closed	-$15.7K	–	1112
2025 Q4	$15.7K	Buy	+10,249	New	+$13.4K	﹤0.01%	982

Other funds holding MAIA

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

StoneX Group's MAIA Position: Q1 2026 in Review

StoneX Group sold out of MAIA Biotechnology (MAIA) in Q1 2026, closing a stake of 10,249 shares — an estimated $15.7K sold.

StoneX Group first reported a position in MAIA in Q4 2025 and held it in 1 quarter. The position peaked at $15.7K in Q4 2025. 33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

StoneX Group reported no remaining MAIA Biotechnology position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 10,249 MAIA Biotechnology shares in Q1 2026, an estimated $15.7K.
StoneX Group first reported a position in MAIA Biotechnology in Q4 2025 and held it in 1 quarter.
StoneX Group's MAIA Biotechnology position peaked at $15.7K in Q4 2025.
33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.